TY - JOUR AU - Freiburghaus, Catja AU - Emruli, Venera Kuci AU - Johansson, Angelica AU - Eskelund, Christian Winther AU - Grønbæk, Kirsten AU - Olsson, Roger AU - Ek, Fredrik AU - Jerkeman, Mats AU - Ek, Sara PY - 2018 DA - 2018/04/25 TI - Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity JO - BMC Cancer SP - 466 VL - 18 IS - 1 AB - The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance. To elucidate the mechanisms responsible for cytarabine resistance, and to create a tool for drug discovery investigations, we established a unique and molecularly reproducible cytarabine resistant model from the Z138 MCL cell line. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-018-4346-1 DO - 10.1186/s12885-018-4346-1 ID - Freiburghaus2018 ER -